Document is current
Any future updates will be listed below
-
Authors
Ebrahimi, Fahim https://orcid.org/0000-0001-5862-966X
Urwyler, Sandrine Andrea https://orcid.org/0000-0003-4056-2262
Betz, Matthias Johannes https://orcid.org/0000-0002-6946-1871
Christ, Emanuel Remigius
Schuetz, Philipp
Mueller, Beat
Donath, Marc Yves
Christ-Crain, Mirjam https://orcid.org/0000-0002-6336-0965
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02672592 at ClinicalTrials.govnct00757276 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome
https://doi.org/10.1038/s41598-021-87207-w
Documents that mention this clinical trial
Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome
https://doi.org/10.1038/s41598-021-87207-w
-
Funding
Funding for this research was provided by:
Schweizerische Akademie der Medizinischen Wissenschaften (YTCR)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3-12346)
- License Information
-
More Information
Article History
Received: 4 January 2021
Accepted: 25 March 2021
First Online: 12 April 2021
Competing interests
: MD is an inventor on patent WO 2004002512 A1. The other authors have nothing to disclose.
